Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADVM Adverum Biotechnologies	$2.46 -5.0%	$2.78	$1.78 ▼ $10.14	$51.39M	0.71	270,637 shs	182,093 shs
GANX Gain Therapeutics	$1.73 -3.9%	$1.86	$0.89 ▼ $3.19	$51.81M	0.11	301,019 shs	220,421 shs
IMUC EOM Pharmaceuticals	$0.10 -2.8%	$0.11	$0.01 ▼ $0.21	$13.26M	0.03	7,300 shs	100 shs
MGX Metagenomi	$1.43 -1.4%	$1.60	$1.23 ▼ $5.63	$53.46M	-0.33	811,276 shs	590,477 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADVM Adverum Biotechnologies	0.00%	-13.07%	+16.04%	-47.99%	-67.72%
GANX Gain Therapeutics	0.00%	-9.90%	-13.93%	-27.92%	+39.52%
IMUC EOM Pharmaceuticals	0.00%	-1.96%	-6.34%	-32.39%	-44.84%
MGX Metagenomi	0.00%	-17.34%	-13.86%	-23.94%	-74.23%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADVM Adverum Biotechnologies	3.9034 of 5 stars	3.4	1.0	0.0	4.8	1.8	2.5	0.6
GANX Gain Therapeutics	2.4982 of 5 stars	3.6	3.0	0.0	0.0	3.4	0.0	0.6
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	2.2864 of 5 stars	3.5	3.0	0.0	0.0	2.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADVM Adverum Biotechnologies	2.80	Moderate Buy	$26.40	973.17% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	373.99% Upside
IMUC EOM Pharmaceuticals	0.00	N/A	N/A	N/A
MGX Metagenomi	3.00	Buy	$13.00	809.09% Upside

Current Analyst Ratings Breakdown

Latest IMUC, MGX, ADVM, and GANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/15/2025	ADVM Adverum Biotechnologies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$5.00 ➝ $4.00
5/15/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $33.00
5/15/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
4/17/2025	ADVM Adverum Biotechnologies	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $33.00
4/16/2025	ADVM Adverum Biotechnologies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$10.00 ➝ $5.00
4/16/2025	ADVM Adverum Biotechnologies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00 ➝ $30.00
4/3/2025	MGX Metagenomi	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $7.00
3/28/2025	GANX Gain Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADVM Adverum Biotechnologies	$1M	51.39	N/A	N/A	$8.26 per share	0.30
GANX Gain Therapeutics	$50K	1,036.13	N/A	N/A	$0.97 per share	1.78
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	$45.26M	1.18	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADVM Adverum Biotechnologies	-$117.17M	-$6.40	N/A	N/A	N/A	N/A	-65.14%	-40.52%	8/11/2025 (Estimated)
GANX Gain Therapeutics	-$22.27M	-$0.86	N/A	N/A	N/A	N/A	-203.91%	-128.05%	8/6/2025 (Estimated)
IMUC EOM Pharmaceuticals	-$1.61M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	-$68.25M	-$2.11	N/A	N/A	N/A	-134.27%	-43.23%	-18.86%	8/13/2025 (Estimated)

Latest IMUC, MGX, ADVM, and GANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
4/15/2025	Q4 2024	ADVM Adverum Biotechnologies	-$1.34	-$1.96	-$0.62	-$1.96	N/A	N/A
3/27/2025	Q4 2024	GANX Gain Therapeutics	-$0.18	-$0.11	+$0.07	-$0.11	N/A	N/A
3/17/2025	Q4 2024	MGX Metagenomi	-$0.62	-$0.63	-$0.01	-$0.63	$13.18 million	$9.61 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADVM Adverum Biotechnologies	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
IMUC EOM Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADVM Adverum Biotechnologies	N/A	5.82	5.82
GANX Gain Therapeutics	0.04	2.99	2.99
IMUC EOM Pharmaceuticals	N/A	N/A	N/A
MGX Metagenomi	N/A	6.18	6.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADVM Adverum Biotechnologies	48.17%
GANX Gain Therapeutics	11.97%
IMUC EOM Pharmaceuticals	N/A
MGX Metagenomi	N/A

Insider Ownership

Company	Insider Ownership
ADVM Adverum Biotechnologies	6.00%
GANX Gain Therapeutics	7.18%
IMUC EOM Pharmaceuticals	3.28%
MGX Metagenomi	17.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADVM Adverum Biotechnologies	190	20.89 million	19.93 million	Optionable
GANX Gain Therapeutics	20	29.95 million	23.42 million	Optionable
IMUC EOM Pharmaceuticals	3	126.50 million	122.35 million	Not Optionable
MGX Metagenomi	236	37.38 million	N/A	N/A

IMUC, MGX, ADVM, and GANX Headlines

Recent News About These Companies

Metagenomi, Inc. (NASDAQ:MGX) Shares Sold by Millennium Management LLC

June 15 at 3:19 AM | marketbeat.com

Insider Selling: Metagenomi, Inc. (NASDAQ:MGX) CEO Sells 10,785 Shares of Stock

June 10, 2025 | insidertrades.com

Metagenomi, Inc. (NASDAQ:MGX) CEO Sells $18,873.75 in Stock

June 9, 2025 | marketbeat.com

Reviewing Metagenomi (NASDAQ:MGX) and Adverum Biotechnologies (NASDAQ:ADVM)

June 6, 2025 | americanbankingnews.com

Metagenomi, Inc. (NASDAQ:MGX) Short Interest Down 18.9% in May

June 3, 2025 | marketbeat.com

Citadel Advisors LLC Decreases Position in Metagenomi, Inc. (NASDAQ:MGX)

June 2, 2025 | marketbeat.com

Northern Trust Corp Raises Position in Metagenomi, Inc. (NASDAQ:MGX)

May 31, 2025 | marketbeat.com

HC Wainwright Analysts Cut Earnings Estimates for Metagenomi

May 30, 2025 | marketbeat.com

Q1 Earnings Forecast for Metagenomi Issued By HC Wainwright

May 29, 2025 | marketbeat.com

Metagenomi, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 16, 2025 | finance.yahoo.com

2MGX : Demystifying Metagenomi: Insights From 4 Analyst Reviews

May 15, 2025 | benzinga.com

Metagenomi Reports Promising Hemophilia A Study Results

May 15, 2025 | tipranks.com

Metagenomi, Inc.: Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 14, 2025 | finanznachrichten.de

Metagenomi Presents Data Highlighting Advancements in Next-Generation Genome Editing Technologies at ASGCT Annual Meeting 2025

May 14, 2025 | globenewswire.com

Metagenomi (MGX) Reports Q1 Loss, Misses Revenue Estimates

May 13, 2025 | zacks.com

Metagenomi Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025 | globenewswire.com

Metagenomi to Present at Upcoming Scientific Meetings

May 2, 2025 | globenewswire.com

Metagenomi Leads The Charge With These 3 Penny Stocks

April 10, 2025 | uk.finance.yahoo.com

Metagenomi price target lowered to $7 from $14 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Metagenomi, Inc. Common Stock (MGX) Latest After Hours Trades

March 31, 2025 | nasdaq.com

Biotech stocks slide as Marks resignation seen being negative for sector

March 31, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMUC, MGX, ADVM, and GANX Company Descriptions

Adverum Biotechnologies NASDAQ:ADVM

$2.46 -0.13 (-5.02%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$2.54 +0.08 (+3.21%)

As of 06/13/2025 05:46 PM Eastern

Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.

Gain Therapeutics NASDAQ:GANX

$1.73 -0.07 (-3.89%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.78 +0.05 (+2.83%)

As of 06/13/2025 07:56 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

EOM Pharmaceuticals OTCMKTS:IMUC

$0.10 0.00 (-2.78%)

As of 06/13/2025 09:30 AM Eastern

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Metagenomi NASDAQ:MGX

$1.43 -0.02 (-1.38%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.70%)

As of 06/13/2025 06:56 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time